Simple biliary atresia score—a validated diagnostic aid for infantile cholestasis
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Jul 2024 · 1 min read
In brief
In brief
This study presents a validated 7-point clinical scoring system combining ultrasound findings (gallbladder length, bile duct diameter, portal vein echogenicity) and laboratory values (bilirubin ratio, GGT) to rapidly identify biliary atresia in jaundiced infants. The score achieved 94-100% sensitivity with a cutoff of ≥3, enabling faster diagnosis and treatment while accurately ruling out BA in approximately two-thirds of cases.
- A 7-point scoring system using gallbladder length, CBD diameter, pre-portal vein echogenicity, D/T bilirubin ratio, and GGT predicts BA risk.
- Score ≥3 identifies BA with 94-100% sensitivity, potentially expediting diagnosis and reducing workup delays in jaundiced infants.
- Direct-to-total bilirubin ratio ≥0.7 and GGT ≥200 IU/L are weighted most heavily (2 points each) in the validated diagnostic algorithm.
- The score accurately ruled out BA in 63-65% of non-BA cholestatic infants, avoiding unnecessary invasive procedures in this population.
- CBD diameter <0.5mm was the most specific parameter (88%) for distinguishing BA from other causes of infantile cholestasis.
Written by the GCMD Library team from the article.
Abstract
Purpose
The workup of jaundiced infants may be variable and protracted, thereby delaying the diagnosis and timely intervention for biliary atresia (BA). This potentially leads to inferior outcomes. We developed a practical score to stratify infantile cholestasis according to the risk of having BA.
Method
The score (0–7) [gallbladder length ≤ 15 mm (+ 1), common bile duct (CBD) diameter < 0.5 mm(+ 1), pre-portal vein (PV) echogenicity(+ 1), direct-to-total bilirubin ratio (D/T) ≥ 0.7(+ 2), and gamma-glutamyl transferase (GGT) ≥ 200 IU/L(+ 2)] are derived from logistic regression of data from a retrospective cohort of cholestatic infants (n = 58, 41 BA) in our institution. It was then validated with a separate retrospective cohort (n = 28, 17 BA) from another institution. Final diagnoses were as per intraoperative cholangiogram (IOC) and liver histopathology.
Results
A cutoff score of ≥ 3 diagnosed BA with 100% and 94% sensitivity in the derivative cohort (area under receiver operating characteristic curve, AUROC 0.869) and validation cohort (AUROC 0.807), respectively. D/T ratio was the most sensitive (93%) and CBD diameter was the most specific (88%) parameter. The score accurately predicted non-BA in 11(65%) and 7(63%) infants in the derivative and validation cohorts, respectively, with one missed BA in the latter.
Conclusion
We propose a validated, simple, yet sensitive diagnostic score to risk-stratify cholestatic infants, aiming to expedite definitive management of BA.